Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

Haematologica

Volumn 94, Issue 3, 2009, Pages 372-379

  Terpos, Evangelos ^a,b   Katodritou, Eirini ^a   Tsiftsakis, Evangelos ^a   Kastritis, Efstathios ^a   Christoulas, Dimitrios ^a   Pouli, Anastasia ^a   Michalis, Eurydiki ^a   Verrou, Evgenia ^a   Anargyrou, Konstantinos ^a   Tsionos, Konstantinos ^a   Dimopoulos, Meletios A ^a   Zervas, Konstantinos ^a  

^a Greek Myeloma Sudy Group   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

Bortezomib; Cystatin c; Multiple myeloma; Renal impairment; Survival

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; CREATININE; CYSTATIN C; DEXAMETHASONE; LACTATE DEHYDROGENASE; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; BONE DISEASE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; MONOTHERAPY; MULTIPLE MYELOMA; NEPHELOMETRY; OUTCOME ASSESSMENT; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CYSTATIN C; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; PYRAZINES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 63149145552     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.000638     Document Type: Article

References (40)

1. San Miguel JF, García-Sanz R. Prognostic features of multiple myeloma. Best Pract Res Clin Haematol 2005;18:569-83.
2. Herrera GA. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory. Ann Diagn Pathol 2000;4:174-200.
3. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 2004;128:875-9.
4. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing?- Nephrol Dial Transplant 2001;16:1042-6.
5. Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med 2008;38:32- 46.
6. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Brú C, GrubbA. Cystatin C as a marker of GFR- history indications, and future research. Clin Biochem 2005;38:1-8.
7. Randers E, Erlandsen EJ, Pedersen OL, Hasling C, Danielsen H. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol 2000; 54:203-9.
8. Jovanovic D, Krstivojevic P, Obra- dovic I, Durdevic V, Dukanovic L. Serum cystatin C and-microglobulin as markers of glomerular nltration rate. Renal Failure 2003;25:123- 33.
9. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312-8.
10. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-6.
11. O'Riordan SE, Webb MC, Stowe HJ, Simpson DE, Kandarpa M, Coakley AJ, et al. Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem 2003;40:648-55.
12. Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens 2006;15:610-6.
13. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395- 406.
14. Lamb EJ, Stowe HJ, Simpson DE, Coakley AJ, Newman DJ, Leahy M. Diagnostic accuracy of cystatin C as a marker of kidney disease in patients with multiple myeloma: calculated glomerular filtration rate formulas are equally useful. Clin Chem 2004;50:1848-51.
15. Heidtmann HH, Salge U, Abraham- son M, Bencina M, Kastelic L, Kopitar-Jerala N, et al. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines. Clin Exp Metastasis 1997;15:368-81.
16. Kos J, Stabuc B, Cimerman N, Brunner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 1998;44:2256-7
17. De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 2002;21:6848-57.
18. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005;103:1195-200.
19. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007;92:- 1411-4.
20. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604-6.
21. lade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. Br J Haematol 1998;102: 1115-23.
22. inney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring Nephelometer Systems (BNA, BN II). Clin Chem 1997;43:1016-22.
23. brahamson M, Dalboge H, Olafsson I, Carlsen S, Grubb A. Efficient production of native, biologically active human cystatin C by Escherichia coli. FEBS Lett 1988; 236:14-8.
24. arfel AH, Zucker-Franklin D, Frangione B, Ghiso J. Constitutive secretion of cystatin C (gamma- trace) by monocytes and macrophages and its downregulation after stimulation. J Exp Med 1987;166: 1912-7.
25. erget-Rosenthal S, Marggraf G, Hiising J, Goring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004;66:1115-22.
26. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005;16:1404-12.
27. Finney H, Williams AH, Price CP. Serum cystatin C in patients with myeloma. Clin Chim Acta 2001; 309:1-6.
28. Payne RB. Creatinine clearance: a redundant clinical investigation. Ann Clin Biochem 1986;23:243-50.
29. 29.Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
30. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N, etal. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007;39: 605-11.
31. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007;48: 337-41.
32. Choi SJ, Reddy SV, Devlin RD, Menaa C, Chung H, Boyce BF, et al. Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption. J Biol Chem 1999;274:27747-53.
33. Bokenkamp A, van Wijk JA, Lentze MJ, Stoffel-Wagner B. Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations. Clin Chem 2002;48:1123-6
34. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-con- taining regimens and the impact of novel agents. Haematologica 2007; 92:546-9.
35. Malani AK, Gupta V, Rangineni R. Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Acta Haematol 2006;116:255-8.
36. 36.Manetti L, Pardini E, Genovesi M, Campomori A, Grasso L, Morselli LL, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005;28:346-9.
37. Risch L, Herklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001;47: 2055-9.
38. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis 2003;42:36-43.
39. Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985;218:499-503.
40. Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, et al. Structure and expression of the human cystatin C gene. Biochem J 1990;268:287-94.